M. Martin

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study

M. Martin, P. Fumoleau, J A Dewar et al. · Annals of Oncology · 2016 · 52 citations

Medicine, Oncology, Pharmacology +16

Carcinoma Ex Pleomorphic Adenoma: Case Report and Options for Systemic Therapy

Negar Chooback, Yaoqing Shen, Martin Jones et al. · Current Oncology · 2017 · 22 citations · Full text

Medicine, Cancer Biology, Oncology +17

Radiologic Evaluation of Small Renal Masses (I): Pretreatment Management

Ana Marhuenda, M. Martin, C. Deltoro et al. · Advances in Urology · 2008 · 15 citations · Full text

Medicine, Radiology, Urology +16

Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors (GF) to TAC. GEICAM Study 9805

M. Martin, Aňa Lluch, Miguel Ángel Seguí et al. · Journal of Clinical Oncology · 2005 · 15 citations

Medicine, Oncology, Pharmacotherapy +17